Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

UCB

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of UCB's 2013 CNS (central nervous system) sales performance.

UCB

Merck decision to drop odanacatib lifts UCB/Amgen

Merck decision to drop odanacatib lifts UCB/Amgen Meanwhile, the decision to take odanacatib out of the running is a boost for UCB and Amgen, who are developing an osteoporosis drug that has been viewed as a close rival

Fitbit eyes pharma partnerships with digital health hire

Fitbit eyes pharma partnerships with digital health hire Wearables are being investigated by pharma companies such as UCB's Parkinson's trial and work by GlaxoSmithKline in neurodegenerative condition ALS, and Fitbit is keen to tap into this interest.

NICE approves UCB Pharma’s Cimzia

NICE approves UCB Pharma’s Cimzia But this new guidance significantly extends the number of patients who could now be eligible for Cimzia, which is already a star performer for UCB. ... UCB has agreed a patient access scheme which sees it providing the first 12 weeks of treatment free of

SMC gives green light for BMS’ Opdivo

SMC gives green light for BMS’ Opdivo 2014. Additionally, the SMC gave three further approvals to Lundbeck's antidepressant Brintellix (vortioxetine), Novartis' Cosentyx (secukinumab) for ankylosing spondylitis, and UCB's Briviact (brivaracetam) for partial-onset seizures in epilepsy

Dr Keith Bragman joins Alacrita

Dr Keith Bragman joins Alacrita He has held a number of senior leadership positions at pharmaceutical companies, including serving as head of global development and research for UCB's Japanese business, vice president and senior partner

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....

Infographics